Semax

Semax is a synthetic heptapeptide based on the fragment 4-10 of adrenocorticotropic hormone (ACTH) with an added Pro-Gly-Pro sequence for enhanced stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it is approved in Russia and Ukraine as a pharmaceutical drug for the treatment of stroke, transient ischemic attacks, peptic ulcers, optic nerve disease, and as a nootropic agent.

Semax exerts its neuroprotective and cognitive-enhancing effects through multiple mechanisms. It increases the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, promotes neurogenesis, and modulates the expression of genes involved in neuronal survival and plasticity. Unlike ACTH itself, Semax does not affect cortisol levels or the adrenal axis, making its nootropic effects independent of hormonal modulation.

Clinical research has demonstrated Semax's efficacy in improving outcomes following ischemic stroke, with studies showing enhanced cognitive recovery and reduced neurological deficits. As a nootropic, research has shown improvements in memory, attention, and learning capacity. Studies have also revealed antioxidant properties, anti-inflammatory effects in the CNS, and the ability to enhance the expression of neurotrophic factors for up to 24 hours following administration. Its favorable safety profile across extensive clinical use in Russia further supports its therapeutic potential.